Shop by goal
Popular compounds
Research resources
Recently viewed
Cagrilintide
Cagrilintide (AM833), long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research.
This strength is out of stock. Pick another strength, or check back soon — restocks are frequent.
From our community
What people say on Facebook
PRECISION. PURITY. PERFORMANCE.
Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.
Shop
Research
Support
Ways to Pay
Shop by goal
Shop by compound
Shop by region
Research use only - all claims made on this site are for testing and research use only. Purchasers must be 21 years of age or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io
Cagrilintide
Compare pack sizes
Tap a pack to select it in the purchase panel above
Buy the 10-pack - save 38%/mg
Buy the 10-pack - save 45%/mg
Single vials ship as an add-on to a 10-vial pack - browse 10-vial packs
Lab-direct quality — full packs or single-vial samples
Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.
Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same lab, same batch, same verified purity — scaled to whatever your research needs.
What It's Researched For
In plain terms, cagrilintide is an appetite-focused compound that works through a different hunger hormone than the GLP-1 family, and is studied especially well in combination with them. It is still investigational. Here is what that looks like across the research.
Appetite & fullness
In clinical research, studied for reducing hunger through the amylin pathway, a separate satiety signal from the GLP-1 compounds.
Weight research
Human trials investigate steady weight reduction on its own, with the effect scaling up as the studied amount increases.
Pairing with GLP-1
Research explores combining it with semaglutide (the CagriSema studies), where the two appetite pathways add together for larger effect.
Blood-sugar & digestion
Studied for slowing how fast the stomach empties and calming post-meal glucose, which complements GLP-1 compounds.
Once-a-week convenience
Designed to stay active for about eight days, so research uses a single weekly injection.
Overview
In short: Cagrilintide (AM833) is a long-acting acylated amylin analogue engineered for once-weekly dosing, with an ~8-day half-life and complementary appetite-suppression mechanism to GLP-1 receptor agonists.
Key research facts
These points summarise lab themes, not human outcomes.
Cagrilintide is an engineered version of human amylin, the 37-amino-acid pancreatic hormone that beta cells release alongside insulin. Native amylin is unstable, forms toxic amyloid fibrils, and has a half-life of only minutes - all of which made it impractical as a research tool before cagrilintide was developed.
The peptide carries a stabilising N14E/V17R salt bridge, anti-fibrillation 25P/28P/29P substitutions adopted from rat amylin (which does not aggregate), a C-terminal proline-to-tyrosine swap that increases calcitonin receptor potency, and a C20 fatty diacid anchor at the N-terminal Lys that binds serum albumin for sustained circulation. Together these modifications turn amylin into a once-weekly research peptide.
Phase 2 dose-finding research (Lancet 2021) reported dose-dependent body-weight reduction with cagrilintide monotherapy, and the Phase 3 REDEFINE 1 trial (NEJM 2025) reported a 20.4% mean reduction versus 3.0% placebo at 68 weeks with the co-formulated Semaglutide combination (CagriSema) - 60% of participants achieving ≥20% and 23% ≥30%. Supplied here as a sterile lyophilised powder for in-vitro and preclinical research only.
Mechanism of Action
Cagrilintide activates all three amylin receptor subtypes plus the calcitonin receptor, modulating arcuate nucleus appetite neurons and slowing gastric emptying - a mechanism complementary to but distinct from GLP-1.
Cagrilintide design (Journal of Medicinal Chemistry, 2021) addresses the three classic problems of using amylin as a research tool: fibril formation (solved by 25P/28P/29P substitutions from non-aggregating rat amylin), proteolytic instability (solved by N14E/V17R helix-stabilising salt bridge), and short half-life (solved by C20 fatty diacid acylation enabling albumin binding, half-life ~159-195 h). The amylin pathway is mechanistically additive to GLP-1 because the two engage distinct appetite circuits - which is why the Phase 3 REDEFINE 1 trial (NEJM 2025) reported larger body-weight reduction for the CagriSema combination (20.4% vs 3.0% placebo at 68 weeks) than is typical for GLP-1 monotherapy alone.
Common Questions People Are Asking
What is cagrilintide and how does it work?
Cagrilintide (AM833) is a long-acting, acylated analogue of the pancreatic hormone amylin. It is a non-selective agonist of the three amylin receptor subtypes (AMY1/2/3R) plus the calcitonin receptor, and acts on arcuate-nucleus appetite neurons to suppress hunger while delaying gastric emptying and lowering postprandial glucagon. A C20 fatty-diacid anchor binds serum albumin to extend its half-life to roughly eight days, supporting once-weekly research dosing.
How is cagrilintide different from a GLP-1 agonist?
GLP-1 agonists activate the GLP-1 receptor. Cagrilintide activates the amylin receptor family (AMY1/2/3R) plus the calcitonin receptor. The two pathways engage different appetite circuits, which is why combining them (as in CagriSema research) produces larger effects than either alone.
What does the research on cagrilintide actually show?
A Phase 2 dose-finding trial (Lancet 2021) reported dose-dependent body-weight reduction with cagrilintide monotherapy. In the Phase 3 REDEFINE 1 trial (NEJM 2025), the cagrilintide + semaglutide combination (CagriSema) reported a 20.4% mean reduction versus 3.0% placebo at 68 weeks on the treatment-policy estimand, with cagrilintide alone around 11.5% and semaglutide alone around 14.9%. These are descriptive clinical-trial findings, not outcomes promised for any use of this research-grade material.
Cagrilintide vs semaglutide - what is the difference?
They act through entirely different hormone systems: semaglutide is a GLP-1 receptor agonist, while cagrilintide is an amylin/calcitonin-receptor agonist. Their half-lives are similar (cagrilintide ~159–195 h, semaglutide ~145–165 h), both supporting once-weekly dosing. In the REDEFINE programme the two were studied together precisely because their satiety pathways are additive rather than redundant.
What side effects were observed in cagrilintide studies?
The most frequently reported events in published trials were gastrointestinal - nausea, vomiting, decreased appetite, constipation or diarrhoea - that were typically mild-to-moderate, escalation-related and transient, plus injection-site reactions. Gallbladder events have been noted in combination research. These are observations recorded in the clinical literature, not a safety profile for any human use of this research material.
Why is the anti-fibrillation design important?
Native human amylin forms amyloid fibrils that are toxic to pancreatic islet cells and make the peptide impractical for sustained research use. Substituting prolines at positions 25, 28, and 29 (borrowed from rat amylin, which does not aggregate) blocks the fibrillation pathway.
How is cagrilintide reconstituted and stored?
Keep the lyophilised powder at −20 °C in the freezer. Reconstitute with bacteriostatic water by directing it down the vial wall rather than onto the powder, then swirl gently - do not shake. After reconstitution, refrigerate at 1–6 °C and protect from light. Avoid repeated freeze-thaw cycles, which can damage the fatty-acid tail.
Is cagrilintide approved or legal?
Cagrilintide is an investigational compound and is not an approved medicine on its own; the CagriSema combination remains in late-phase clinical development. The material supplied here is unapproved, research-grade laboratory material sold strictly for in-vitro and preclinical research use only - not for human use.
What happens if you stop taking peptides?
It depends on the peptide class. Cagrilintide is a long-acting amylin analogue studied for appetite and metabolic research, often alongside GLP-1 peptides. As with the GLP-1 class, the research literature on appetite-regulating peptides indicates the appetite effects depend on continued receptor stimulation, so they wane once administration stops and the compound clears; cagrilintide's long half-life means that clearance is gradual. These observations come from research and clinical studies; cagrilintide here is an unapproved research-grade peptide.
Where can I buy Cagrilintide?
Right here - Cagrilintide is supplied directly by New-U Research Compounds on this page. Every batch is independently third-party tested to >99% HPLC purity with a batch-linked Certificate of Analysis, supplied as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging.
How much does Cagrilintide cost?
Cagrilintide pricing is shown live on this page, per pack size - 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, every order includes the batch Certificate of Analysis, and shipping is free on orders over $350.
Is Cagrilintide third-party tested?
Yes. Every Cagrilintide batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC. Every order ships with its COA, and current batch certificates are published on our COA page.
How do I buy Cagrilintide?
Add the Cagrilintide pack size you need to your cart and check out: enter your shipping details, then choose your payment method - cryptocurrency or card - on the next step. Every order ships with its batch Certificate of Analysis (COA).
What payment methods can I use to buy Cagrilintide?
At checkout you can pay by card or crypto. New-U supports BTC and selected stablecoin and network-asset payments across Ethereum, Solana, TRON, Polygon, Base, BNB Chain and Linea. You choose your method after confirming your order.
How fast is shipping, and do you ship worldwide?
Yes - we ship worldwide in discreet, unmarked, temperature-stable, tracked packaging. Delivery typically takes 6–14 business days, and shipping is free on orders over $350.
Research use only - all claims made on this site are for testing and research use only.
Pharmacokinetics
Research-Observed Effects
Published Research Context
In the published clinical literature, subcutaneous cagrilintide was titrated gradually - the dose-finding and combination programmes stepped up from 0.25 mg once weekly through 0.5, 1.0 and 1.7 mg toward a 2.4 mg maintenance level over roughly 16–20 weeks, with the CagriSema combination co-formulating 2.4 mg cagrilintide with 2.4 mg semaglutide. These figures describe the escalation schedules reported in published trials and are recorded here as research context only.
Stacking Compatibility
Compatible compounds
Avoid combinations
Side Effects (Observed in Literature)
Common
Rare
Dose-dependent
Evidence Tier
Overall: Tier 1: Human clinical
Cagrilintide has human Phase 2 monotherapy data and pivotal Phase 3 combination (CagriSema) data, though it remains investigational and is not an approved medicine. The research-grade material supplied here is unapproved laboratory material.
Tier 1 · Human clinical
Certificates, databases & peer-reviewed sources
Last reviewed: 16 June 2026 · New-U Research Compounds
Key Characteristics
Specifications
About Cagrilintide (AM833): Long-Acting Amylin Analogue Research Guide
Cagrilintide (AM833) is a long-acting, acylated amylin analogue and the first amylin-pathway agonist stable enough for sustained, once-weekly research use. Native human amylin forms toxic amyloid fibrils in vitro and has a circulating half-life of minutes; cagrilintide solves both problems through anti-fibrillation proline substitutions borrowed from non-aggregating rat amylin plus a C20 fatty-diacid anchor that reversibly binds serum albumin to extend the half-life to roughly eight days.
The defining research finding for cagrilintide is mechanistic complementarity with the GLP-1 class: amylin and GLP-1 act on distinct appetite circuits, so co-administering them shifts body composition more than either alone. That is the basis of the CagriSema programme - in the Phase 3 REDEFINE 1 trial (NEJM 2025) the combination reported a 20.4% mean body-weight reduction versus 3.0% placebo at 68 weeks on the treatment-policy estimand, with cagrilintide and semaglutide monotherapy arms each landing between those figures.
Supplied here as a sterile lyophilised powder for in-vitro and preclinical laboratory research only. Cagrilintide is an investigational compound, is not a licensed pharmaceutical product, and is not a substitute for any prescribed medication.
Customer Reviews
No customer reviews yet - be the first to share your experience.
More in Metabolic Research
Cagrilintide vs related Metabolic Research compounds
Descriptive catalog comparison for research sourcing decisions - not dosing guidance.
More on Cagrilintide
Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.